It is widely accepted that neuronal energy crisis, cerebral hypometabolism and vascular hypoperfusion are major and potentially treatable contributors to the loss of functioning in patients with Alzheimer disease (AD). In addition, recently we have found an unexpected capacity for melanin to dissociate water and aid in deriving energy in the process. We hypothesize that melanin can be used as a new and more effective therapeutic approach in the treatment of AD patients. The goal of our work is to potentially target melanin's dissociation properties for therapy of the disease by using a combination of selective mitochondrial antioxidant plus the Melanin analogue (QIAPI-1) both in combination with our recently developed brain exercising program. This study applies the brain hypometabolism paradigm to AD patients in order to analyze cognitive function in the patients who receive Alpha-Lipoic Acid, Acetyl-L-Carnitine, Omega-3-6-9 from Fish, Flax, Borage oil as well as Coenzyme Q-10 and Melanin analogue (QIAPI-1, developed by Dr. Solis), along with diet changes in combination with and our recently developed brain activation program (a home-based protocol involving mild physical exercise and cognitive training. The average age of patients were 73.5. These patients were evaluated at baseline and in one and two years post treatment. Our clinical results showed that patients who received the combination of mitochondrial antioxidants and QIAPI-1 presented the maximum significant cognitive improvement at the end of 24 months of treatment. The maximum significant cognitive improvement was seen with the combined treatment in MMSE, attention, memory, naming, construction, clock drawing, verbal fluency, and Ruff Frontal Fluency tests. By the end of 24 months of the treatment, significant improvement was especially observed in attention, construction and clock drawing when patients received combined treatment. In addition, this group also showed that rest of the tests no signs of decreases and/or decline below base line for the entire period of the treatment. Further examination of the potential pharmacologic modulation of brain hypometabolism by using human photosynthesis compounds such as selective mitochondrial antioxidants and Melanin analogue represents a completely new and more effective strategies to treat Alzheimer and/or other dementia types.